

WestminsterResearch

<http://www.westminster.ac.uk/westminsterresearch>

**The Visually Induced Motion Sickness Susceptibility
Questionnaire (VIMSSQ): Estimating Individual Susceptibility to
Motion Sickness-Like Symptoms When Using Visual Devices.
Golding, J.F.**

This is a copy of the accepted author manuscript of the following article: Golding, J.F. 2021. The Visually Induced Motion Sickness Susceptibility Questionnaire (VIMSSQ): Estimating Individual Susceptibility to Motion Sickness-Like Symptoms When Using Visual Devices. *Human Factors: The Journal of the Human Factors and Ergonomics Society*. The final definitive version will be available from the publisher Sage at:

<http://www.uk.sagepub.com/journals/Journal201912>

© The Author(s) 2021

The WestminsterResearch online digital archive at the University of Westminster aims to make the research output of the University available to a wider audience. Copyright and Moral Rights remain with the authors and/or copyright owners.

VIMSSQ: DEVELOPMENT AND VALIDATION

1 **The Visually Induced Motion Sickness Susceptibility Questionnaire (VIMSSQ): Estimating**
2 **individual susceptibility to motion sickness-like symptoms when using visual devices**

3

4 Behrang Keshavarz^{1,2}, Brandy Murovec^{1,2}, Niroshica Mohanathas^{1,3}, John F. Golding⁴

5 ¹The KITE Research Institute, Toronto Rehab–University Health Network, Toronto, ON, Canada

6 ²Department of Psychology, Ryerson University, Toronto, ON, Canada

7 ³Department of Psychology, University of Toronto, Toronto, ON, Canada,

8 ⁴Department of Psychology, University of Westminster, London, UK

9

10 MANUSCRIPT TYPE: Extended multi-phase study

11

12 WORD COUNT: 5,315

13

14 ACKNOWLEDGEMENTS:

15 Correspondence concerning this article should be addressed to: Dr. Behrang Keshavarz, The

16 KITE Research Institute, Toronto Rehab-University Health Network, 550 University Avenue,

17 Toronto, ON M5G 2A2, Canada. behrang.keshavarz@uhn.ca.

18 BK is supported by a Discovery Grant from the Natural Sciences and Engineering Council (NSERC) of

19 Canada RGPIN-2017-04387.

20 We like to thank Dr. Dave Flora for his comments regarding the statistical analysis and Robert

21 Shewaga for helping with the laboratory setup.

22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

Abstract

Objective: Two studies were conducted to develop and validate a questionnaire to estimate the individual susceptibility to visually induced motion sickness (VIMS). **Background:** VIMS is a common side-effect when watching dynamic visual content from various sources, such as Virtual Reality, movie theatres, or smartphones. A reliable questionnaire tool to predict the individual susceptibility to VIMS is currently missing. The aim was to fill this gap by introducing the Visually Induced Motion Sickness Susceptibility Questionnaire (VIMSSQ). **Methods:** Two independent studies were conducted: A survey and an experimental study. *Survey:* The VIMSSQ investigated the frequency of nausea, headache, dizziness, fatigue, and eyestrain when using different visual devices. Data were collected from a survey of 322 participants for the VIMSSQ and other related phenomena such as migraine. *Experimental study:* 23 participants were exposed to a rotating visual stimulus that induced VIMS. Participants filled out the VIMSSQ together with other questionnaires and rated their level of VIMS using the Simulator Sickness Questionnaire (SSQ). **Results:** *Survey:* The most prominent symptom when using visual devices was eyestrain, and females reported more VIMS compared to males. *Experimental study:* regression analyses suggested that the VIMSSQ is a valuable tool for predicting VIMS ($R^2 = .34$) as measured by the SSQ, particularly when used in conjunction with other questions pertaining to the tendency to avoid visual displays and experience syncope ($R^2 = .59$). **Conclusion:** We generated normative data for the VIMSSQ and demonstrated its validity. **Application:** The VIMSSQ can become a valuable and important tool to predict one's susceptibility to VIMS based on self-reports.

Keywords: simulator sickness, cybersickness, virtual reality, sex, migraine

VIMSSQ: DEVELOPMENT AND VALIDATION

45 **Précis**

46 The Visually Induced Motion Sickness Susceptibility Questionnaire (VIMSSQ) was developed
47 and validated across two studies. In conjunction with other measures, the VIMSSQ explained
48 59% of the variance in VIMS as measured by the SSQ. We conclude that the VIMSSQ is a
49 valuable tool for estimating individual susceptibility to VIMS.

50

51

52 **Introduction**

53 Visually induced motion sickness (VIMS) is a phenomenon similar to traditional motion
54 sickness and is characterized by a variety of symptoms related to gastric activity (e.g., nausea,
55 vomiting, stomach awareness), autonomic responses (e.g., pallor, sweating), arousal (e.g.,
56 fatigue, drowsiness, difficulty concentrating), disorientation (e.g., dizziness, vertigo), and/or
57 oculomotor issues (e.g., eyestrain, blurred vision, headache) (Bos et al., 2008; Golding & Gresty,
58 2015; Robert S. Kennedy et al., 2010; Keshavarz et al., 2014). In contrast to traditional motion
59 sickness, actual physical movement is typically missing during VIMS and symptoms are
60 primarily caused by stimulation of the visual system. The symptomatology of VIMS and
61 traditional motion sickness are very similar, with oculomotor issues such as eyestrain and blurred
62 vision being more common in VIMS. Depending on the visual device, various terms have been
63 used in the literature to describe specific types of VIMS, including video gaming sickness (Frey
64 et al., 2007), Cinerama sickness, Virtual Reality (VR) sickness (Cobb et al., 1999), cybersickness
65 (K. M. Stanney & Kennedy, 1997) or simulator sickness (Kennedy et al., 1989). Here, we use
66 VIMS as a general term that includes all these subcategories. Note that the use of simulators and
67 VR may involve physical motion in certain cases (e.g., motion-based simulators, head tracking in
68 VR), and symptoms experienced using these devices may strictly speaking not be purely visually
69 induced; however, as the visual system is arguably the main contributor to motion sickness-like
70 sensations in these cases, we will include them under the umbrella of VIMS in the present paper.

71 The exact prevalence of VIMS remains unclear, but laboratory research suggests that the
72 percentage of people experiencing VIMS can vary widely from 1% (Klüver et al., 2015) to 80%
73 under certain circumstances (Cobb, 1999; Stanney, Mourant, et al., 1998; Stanney et al., 1999),

VIMSSQ: DEVELOPMENT AND VALIDATION

74 depending on several factors such as the VR equipment (Frank et al., 1988; Moss & Muth,
75 2011), the experimental setup (e.g., field-of-view, Bos et al., 2010; Duh et al., 2002), or the
76 visual content (Bubka et al., 2007; Keshavarz, Philipp-Muller, et al., 2018; Palmisano et al.,
77 2007). Additionally, several factors affect an individual's susceptibility to VIMS. For instance,
78 females have been found to report more VIMS than males (Flanagan et al., 2005; Stanney et al.,
79 2020), although the robustness of this finding remains unclear given that some studies could not
80 identify sex-related differences (Curry et al., 2020; Klosterhalfen et al., 2006). Age has been
81 discussed as another prominent factor, with older adults often reporting more VIMS compared to
82 younger adults (Domeyer et al., 2013; Keshavarz, Ramkhalawansingh, et al., 2018). In the
83 present study, we will consider age and sex-related differences to further enhance our
84 understanding about the role of these two factors.

85 The elevated risk for experiencing VIMS is critical for several reasons. VR technologies
86 have dramatically improved over the last decade, while being affordable and accessible to a
87 broad population. Several VR systems (e.g., Oculus Rift, HTC Vive, Playstation VR) offer a
88 highly realistic, immersive, and multisensory VR experience. In 2018 alone, 3.6 million VR
89 devices were sold world-wide and these numbers are expected to increase. VR is no longer a
90 niche product, but is rather a common tool in several domains, including rehabilitation (Massetti
91 et al., 2018), education (Radianti et al., 2020), research (Loomis et al., 1999), training
92 (Adamovich et al., 2009), mental health (Rizzo et al., 1998), clinical assessment (Rizzo, 2014),
93 and personal entertainment (Bates, 1992). The risk of experiencing VIMS can have a dramatic
94 impact on VR technologies from an economic standpoint and may jeopardize the success and
95 acceptability of these technologies. However, VIMS poses a health concern not only when using
96 VR systems, but also for other visual devices such as video games, cinemas, smartphones, and/or

VIMSSQ: DEVELOPMENT AND VALIDATION

97 tablets. Although symptoms associated with VIMS are typically short-lived and resolve within
98 minutes after stopping, they can occasionally last for several hours and affect the user's daily
99 activities (Stanney et al., 1998; Stanney et al., 1999). In addition, VIMS is particularly
100 problematic for those with compromised health conditions, where symptoms such as nausea,
101 headache, or dizziness may worsen an underlying medical condition such as migraines and
102 vestibular disorders. Our modern society increasingly relies on visual technologies and the
103 problems associated with VIMS will become even more important in the near future.

104 Over the past decades, several techniques have been introduced to reduce or prevent
105 VIMS. The list of countermeasures is long and ranges from simple recommendations about the
106 distance to the visual screen (Bos et al., 2010; Duh et al., 2002), behavioral methods (Keshavarz,
107 2016; Yen Pik Sang, Billar, et al., 2003), to more complex pharmacological treatments (Golding
108 & Gresty, 2015). The latter is often associated with unwanted side-effects such as drowsiness
109 and is therefore not a feasible solution in most situations. Non-pharmacological treatments such
110 as music (Keshavarz & Hecht, 2014; Peck et al., 2020), controlled breathing (Yen Pik Sang,
111 Golding, et al., 2003), visual reference about true gravity vertical (Duh et al., 2004; Prothero et
112 al., 1999), or airflow (D'Amour et al., 2017) can be effective under certain circumstances, but
113 none of these measures fully prevent VIMS. The most effective treatment available so far
114 remains habituation (Hill & Howarth, 2000; Smither et al., 2008). That is, repeated exposure to
115 the same, nauseating stimulus eventually results in reduced VIMS over time, even in severe
116 cases of VIMS (Rine et al., 1999). However, habituation is time consuming and the specific
117 tolerance acquired from one type of visual technology may not always generalize to other VIMS-
118 inducing situations.

VIMSSQ: DEVELOPMENT AND VALIDATION

119 Given the lack of reliable methods to prevent VIMS, it is of utmost importance to identify
120 those who are at risk of experiencing VIMS. Unfortunately, reliable methods to predict the
121 susceptibility to VIMS do, to the best of our knowledge, not yet exist. Several methods have
122 been introduced in the past that measure the severity of VIMS *after* exposure to a VIMS-
123 inducing stimulus, such as the Misery Index((Bos, 2015), the Nausea Profile (Muth et al., 1996),
124 the Fast Motion Sickness Scale (Keshavarz & Hecht, 2011), or the Simulator Sickness
125 Questionnaire (SSQ, Kennedy et al., 1993). In contrast, no tool exists that can be assessed *prior*
126 to a VIMS inducing stimulus in order to estimate one's susceptibility to VIMS. Golding
127 introduced the Motion Sickness Susceptibility Questionnaire (MSSQ; Golding, 1998, 2006) to
128 predict an individual's susceptibility to traditional motion sickness. The MSSQ inquires about a
129 person's past history of motion sickness as a child or adult. The use of the MSSQ has become
130 best practice to predict traditional motion sickness, however, the MSSQ was not designed to
131 predict VIMS. In fact, items referring to visual devices have been deliberately removed from the
132 MSSQ during the development process because, at the time, visual devices as we know them
133 today were not as common, and including these items did not add to the overall predictive power
134 of the MSSQ. Since new visual technologies have greatly increased and can now be considered
135 mainstream, a tool that focuses on the susceptibility of VIMS is highly desirable. Thus, our
136 objective is to fill this void by introducing a novel method to predict the susceptibility to VIMS –
137 the Visually Induced Motion Sickness Susceptibility Questionnaire (VIMSSQ). Importantly,
138 note that the VIMSSQ was designed as an addition to the MSSQ, and not a necessarily as
139 substitute thereof.

140 The present paper consists of two main parts. In the first part, we will describe the
141 development of the VIMSSQ and its relationship to other possible risk factors such as classical

VIMSSQ: DEVELOPMENT AND VALIDATION

142 motion sickness susceptibility, migraine, or dizziness. We will present data from a survey with N
143 = 322 participants using the VIMSSQ. In the second part, we will present empirical findings
144 from an experimental study that show the usefulness of the VIMSSQ in predicting VIMS. In this
145 experimental study, we applied the VIMSSQ prior to exposing participants to a VIMS-inducing
146 stimulus. VIMS was measured after stimulus exposure using the Simulator Sickness
147 Questionnaire (SSQ, Kennedy et al., 1993), a widely used questionnaire assessing the severity
148 and symptomatology of VIMS.

149 **Part 1: Development and normative data of the VIMSSQ - Survey study**

150 **Methods**

151 **Development of the VIMSSQ**

152 *Questionnaire structure.* The VIMSSQ was developed with the MSSQ-short (Golding,
153 2006) in mind. That is, we adopted the assumption that previous incidences of VIMS can
154 successfully predict future episodes of VIMS. However, as the symptomatology of VIMS is
155 more diverse compared to traditional motion sickness (e.g., more oculomotor issues and
156 dizziness; (Lawson, 2014; K. M. Stanney & Kennedy, 1997), we decided to inquire about the
157 frequency of specific symptoms when using visual devices, rather than asking for an overall
158 estimation of the level of VIMS for each visual device. Note that this is in contrast to the MSSQ,
159 which asks how often participants experienced motion sickness without looking at different
160 symptoms separately. Thus, the VIMSSQ focuses on 5 symptoms: nausea, headache, dizziness,
161 fatigue, and eyestrain. Nausea and fatigue are cardinal symptoms of both VIMS and traditional
162 motion sickness, whereas headache, dizziness, and eyestrain are more pronounced in VIMS than
163 in traditional motion sickness (Golding & Gresty, 2005; Keshavarz et al., 2014; Lawson, 2014).
164 As previously mentioned, the list of other symptoms for VIMS is long and can include pallor,

VIMSSQ: DEVELOPMENT AND VALIDATION

165 sweating, burping, blurred vision, general discomfort, vertigo etc.. However, in order to reduce
166 the number of symptoms for inclusion in the VIMSSQ, we decided to focus on symptoms that
167 (a) are most common in VIMS and (b) the user can easily relate to (e.g., it is difficult to self-
168 observe pallor).

169 The frequency of each of the 5 symptoms had to be rated for 11 common visual devices.
170 The visual devices included 2D movie theater, 3D movie theater, IMAX theater, smartphone
171 (dynamic content like movies), tablet (dynamic content like movies), TV, video games (console
172 or computer), Head Mounted Displays/VR glasses, stationary platform simulators, moving
173 platform simulators, large public moving display advertising or information screen. The
174 frequency of each symptom had to be rated on a 4-point Likert scale (*never, rarely, sometimes,*
175 *often*) for experiences during adulthood (18 years or older), ignoring childhood experiences;
176 participants could also indicate if they never used a visual device (*never used/not applicable:*
177 *n/a*).

178 In addition, the VIMSSQ included a part that asked the user about their habits of using
179 the above mentioned 11 visual devices (*How often have you used or experienced any of these*
180 *devices or displays during adulthood?*). Again, participants could choose between *never, rarely,*
181 *sometimes,* and *often*. This section allowed the researcher to gain insights into how common the
182 usage of different visual displays is and it may help to detect differences between populations in
183 terms of their proficiency with these devices and displays. Finally, a single question at the end of
184 the VIMSSQ inquired whether participants stopped using any of these devices due to increased
185 discomfort (*Have any of these symptoms stopped you from using any of these devices or made*
186 *you actively avoid viewing such displays?*). If participants responded with *yes*, they were asked
187 to list the types of devices that they stopped using in a free response format. (Note that for the

VIMSSQ: DEVELOPMENT AND VALIDATION

188 final version of the VIMSSQ, we decided to change the response format for the avoidance
189 question to match the VIMSSQ response format: 0 = *never*, 1 = *rarely*, 2 = *sometimes*, 3 = *often*).
190 Overall, the VIMSSQ contained 67 items: 11 items regarding the usage frequency of visual
191 displays and devices, 55 items regarding the frequency of each of the five symptoms, and 1
192 question regarding the avoidance of any visual devices and displays.


193 *Scoring.* The scoring of the VIMSSQ follows Golding's procedure for calculating the
194 MSSQ scores (Golding, 2006). That is, responses for each item are assigned a numeric value (0
195 = *never*, 1 = *rarely*, 2 = *sometimes*, 3 = *often*, n/a = *never used/not applicable*). To calculate
196 scores for each of the five subscales nausea (VIMSSQ-N), headache (VIMSSQ-H), dizziness
197 (VIMSSQ-D), fatigue (VIMSSQ-F), and eyestrain (VIMSSQ-ES), the following procedure is
198 applied (see Figure 1): For each subscale, the number of types of visual devices and displays not
199 used by the participant is identified and counted (i.e., the total number of n/a – *not used*
200 responses, maximum = 11). Next, for each subscale, the score for each of the 11 types of
201 devices/displays is calculated by summing the raw scores for each item (n/a responses counted as
202 zero). To ultimately calculate each VIMSSQ subscale, we used the formula:

$$203 \quad (\text{raw subscale score}) * (11) / (11 - \text{n/a total})$$

204 with 'raw subscale score = score for either nausea, dizziness, fatigue, headache, or
205 eyestrain' and 'n/a total = the total number of n/a responses'. If no types of visual devices are
206 experienced, an error due to a division by *zero* would occur, making it not possible to calculate a
207 VIMSSQ score and estimate VIMS susceptibility, which also provides an internal consistency
208 check. The maximum score for each VIMSSQ subscale is 33. A VIMSSQ total score (VIMSSQ-
209 TS) can be calculated by summing the five subscales.

VIMSSQ: DEVELOPMENT AND VALIDATION

210 **Figure 1**
 211 *Scoring procedure for the VIMSSQ subscales (upper panel) and the VIMSSQ total score (lower*
 212 *panel).*



213
 214 *Note.* Refer to the text for a detailed description of the scoring procedure.

215

216 **Participants**


217 A total of 332 participants filled out the VIMSSQ either via an online survey using the
 218 platform Qualtrics (n = 140) or as a paper-and-pencil version when they attended experimental
 219 studies at The KITE Research Institute-University Health Network (n = 192). In both cases,
 220 participants gave their written consent first before filling out the VIMSSQ. The online survey
 221 was approved by the research ethics boards of the University Health Network, Canada, and the
 222 University of Westminster, United Kingdom. The respective study protocols for the paper-and-
 223 pencil version of the VIMSSQ were all approved by the research ethics board of the University
 224 Health Network, Canada. Ten participants were removed from the data analysis due to
 225 incomplete data sets, resulting in a final sample size of $N = 322$ ($M_{\text{age}} = 32.89$ years, $SD_{\text{age}} =$
 226 18.82). The sample consisted of 195 females ($M_{\text{age}} = 31.26$ years, $SD_{\text{age}} = 17.53$) and 126 males
 227 ($M_{\text{age}} = 35.38$ years, $SD_{\text{age}} = 20.45$). As differences between females and males have been
 228 suggested with regards to VIMS severity (Flanagan et al., 2005; Stanney et al., 2020) we will

VIMSSQ: DEVELOPMENT AND VALIDATION

229 consider sex as a factor in our analysis. Note that one participant chose not to answer the
230 question regarding their sex and was therefore excluded from all sex-related statistical analysis.
231 A detailed description of the age distribution of the sample is given in Figure 2.

232 **Figure 2**

233 *Participants' age distribution separated by sex.*



234

235 **Other baseline measures**

236 In addition to the VIMSSQ, participants filled out questionnaires related to concepts
237 relevant to VIMS, including their susceptibility to traditional motion sickness, migraines, and the
238 impact of dizziness on daily living. Motion sickness susceptibility was measured using the short
239 version of the MSSQ (Golding, 2006). The MSSQ inquires about the frequency of motion
240 sickness (*not applicable, never, rarely, sometimes, often*) when travelling or using different
241 modes of transportation (e.g., car, bus, ship, airplane, funfair rides) as a child (before the age of

VIMSSQ: DEVELOPMENT AND VALIDATION

242 12) and as an adult (last 10 years). The tendency to experience migraines has been linked to the
243 experience of VIMS in the past (Golding & Patel, 2017) and was measured using the Migraine
244 Screen Questionnaire (Láinez et al., 2010), consisting of five items that are rated on a binary
245 scale (0 = no, 1 = yes). Questions include whether a person experiences frequent or intense
246 headaches and whether the headaches last more than four hours. A total score was calculated by
247 summing the values for each response (max. score = 5), with a score of 4 or higher indicates high
248 propensity to experience migraines. The SWID4, a set of four social, travel, family and work-
249 related questions which has been validated previously (Bronstein et al., 2010) was used to assess
250 the impact of dizziness on social life and work. Participants had to provide yes or no responses to
251 these questions, and the values (no = 0, yes = 1) were summed together to create a total score for
252 SWID (max. score = 4). A single binary item concerning the susceptibility to vasovagal syncope
253 and facilitating factors, circumstances, and symptoms (derived from Bosser et al., 2006) was
254 added.

255 **Results**


256 **Device usage**

257 An overview of the usage of visual devices is provided in Figure 3 for male and female
258 participants. To account for the nonnormality of the data (ordinal scales), non-parametric
259 Wilcoxon Rank-Sum tests were calculated to detect differences in the frequency of visual device
260 usage for males and females. Results showed that male participants played significantly more
261 video games than female participants ($W = 8080.50, p < .001$). No other sex-related differences
262 were found for any of the other visual devices.

263 **Figure 3**

VIMSSQ: DEVELOPMENT AND VALIDATION

264 *Relative frequency of device usage (in percent) for females (top panel), males (center panel), and*
 265 *for both combined (bottom panel)*



266
 267 **Symptom frequency, VIMSSSQ scores, device avoidance, and sex**
 268 The frequency of each VIMS-related symptom for each of the visual devices is shown in
 269 Figure 4. The mean scores for the VIMSSQ subscales nausea, dizziness, fatigue, headache, and
 270 eyestrain as well as the VIMSSQ total score are shown in Figure 5 for female and male
 271 participants. Detailed statistical information including percentiles for each VIMSSQ subscale are
 272 given in Table 1. Independent samples *t* tests (degrees of freedom corrected for unequal
 273 variances, Holm-corrected alpha level, Cohen’s *d* as effect size) were calculated to investigate

VIMSSQ: DEVELOPMENT AND VALIDATION

274 sex-related differences with regards to the VIMSSQ subscales. Females reported significantly
275 higher scores for the VIMSSQ subscales dizziness, $t(278) = 2.625, p = .025$, headache, $t(309) =$
276 $4.327, p < .001, d = .47, d = .30$, fatigue, $t(296) = 2.476, p = .025, d = .27$, eyestrain, $t(291)$
277 $= 3.120, p = .002, d = .35$, and the total score, $t(291) = 3.577, p < .001, d = .40$. No significant
278 difference showed for the VIMSSQ subscale nausea, $t(257) = 1.660, p = .086, d = .19$.


279 Overall, 29.5% of all users indicated that the presence of VIMS-related symptoms caused
280 them to stop (or significantly reduce) the use of certain visual devices. The most common
281 devices that users try to avoid include 3D movies (14.3%), smartphones (5.3%), IMAX theatres
282 (4.3%), video games (3.4%), simulators (4.0%), and VR (2.8%).

283

284

285 **Figure 4**

286 *Relative frequency of reported symptoms for each of the visual devices averaged across sex*




287

VIMSSQ: DEVELOPMENT AND VALIDATION

288 *Note.* Participants who never have used a particular visual device were removed to enhance
289 comparability across devices, resulting in different sample sizes for TV ($n = 309$), smartphone (n
290 $= 293$), tablet ($n = 272$), 2D movies ($n = 310$), 3D movies ($n = 288$), IMAX theatre ($n = 256$),
291 videogames ($n = 252$), simulator moving ($n = 189$), simulator stationary ($n = 298$), VR ($n = 119$),
292 and commercial displays ($n = 262$).

293 **Figure 5**

294 *Mean scores for the VIMSSQ subscales nausea, headache, dizziness, fatigue, and eyestrain*
295 *averaged across visual devices and separated by sex.*



296
297 *Note.* Error bars represent *SD*. Single dots represent individual scores for each participant.

298 * $p < .05$, ** $p < .01$, *** $p < .01$.

VIMSSQ: DEVELOPMENT AND VALIDATION

299 **Table 1**

300 *Descriptive statistics for the VIMSSQ subscales separated by sex*

FEMALE (n = 195)								
VIMSSQ	M	SD	Range	P10	P25	Med	P75	P90
Nausea	4.39	4.96	0 – 20.9	0.00	0.00	3.00	6.29	11.50
Headache	6.62	6.91	0 – 26.4	0.00	0.00	4.71	11.00	17.95
Dizziness	4.29	4.99	0 – 23.22	0.00	0.00	2.75	6.94	12.31
Fatigue	6.35	7.39	0 – 33.00	0.00	0.00	3.67	11.00	16.30
Eyestrain	10.94	8.34	0 – 33	0.00	3.90	9.62	16.75	22.66
Total score	32.59	26.52	0 – 105.6	2.75	11.00	26.40	49.19	71.50
MALE (n = 126)								
VIMSSQ	M	SD	Range	P10	P25	Med	P75	P90
Nausea	3.42	5.22	0 – 24.44	0.00	0.00	0.00	5.30	11.50
Headache	3.65	5.33	0 – 28.11	0.00	0.00	1.47	4.93	10.31
Dizziness	2.84	4.71	0 – 30.56	0.00	0.00	1.05	4.09	7.62
Fatigue	4.44	6.29	0 – 33	0.00	0.00	1.22	6.81	12.70
Eyestrain	8.19	7.30	0 – 33	0.00	2.44	6.94	12.43	16.50
Total score	22.54	23.23	0 – 146.67	0.00	6.70	16.50	30.25	51.56
TOTAL (N = 322)								
VIMSSQ	M	SD	Range	P10	P25	Med	P75	P90
Nausea	4.00	5.07	0 – 24.44	0.00	0.00	2.10	6.29	11.90
Headache	5.44	6.49	0 – 28.11	0.00	0.00	2.75	8.25	15.12
Dizziness	3.71	4.92	0 – 30.56	0.00	0.00	2.00	5.50	11.00
Fatigue	5.62	7.02	0 – 33.00	0.00	0.00	2.88	9.90	15.68
Eyestrain	9.87	8.80	0 – 33.00	0.00	3.00	8.80	14.58	20.61
Total score	28.62	25.68	0 – 146.67	1.83	9.17	22.00	41.95	66.00

301 *Note.* Med = Median, P10 = 10th Percentile, P25 = 25th Percentile, P75 = 75th Percentile, P90 =

302 90th Percentile

VIMSSQ: DEVELOPMENT AND VALIDATION

303 **Scale reliability and factor analysis**

304 An exploratory factor analysis was conducted on the VIMSSQ subscales nausea,
 305 dizziness, fatigue, headache, and eyestrain (frequency of use and avoidance items were omitted)
 306 to examine the factor structure of the VIMSSQ. Bivariate distributions between each variable did
 307 not suggest the presence of nonlinearity. To account for ordinal nature of the items comprising
 308 each subscale, Spearman rank-ordered correlations (N = 322) were utilized for the factor analysis
 309 and were all significant (Table 2).

310 **Table 2**

311 *Spearman correlations between VIMSSQ subscale measures*

	VIMSSQ subscale				
	Nausea	Headache	Dizziness	Fatigue	Eyestrain
Nausea	1.00				
Headache	.59	1.00			
Dizziness	.58	.53	1.00		
Fatigue	.34	.56	.42	1.00	
Eyestrain	.44	.69	.45	.63	1.00

312 *Note.* All correlations are significant at $p < .001$.

313 Due to violations of the multivariate normality assumption as assessed by Mardia's Test
 314 (skewness coefficient = 622.76, $p < .001$; kurtosis coefficient = 29.57, $p < .001$), a Weighted Least
 315 Squares (WLS) estimation method was chosen (Flora & Curran, 2004). All factor models were
 316 estimated using the lavaan Package (Rosseel, 2012) on the statistical software R (version 4.0.2;
 317 R Core Team, 2020). Results suggested a one-factor solution for the set of 5 VIMSSQ subscales
 318 (Eigenvalue: 3.27), with a reasonable model fit for the latent factor accounting for 57% of the
 319 variance (root-mean-square residuals = .07). All variables had factor loadings of at least .68 and
 320 communality values within the range of .46 (VIMSSQ-N) and .77 (VIMSSQ-H). Specifically, it

VIMSSQ: DEVELOPMENT AND VALIDATION

321 was found that for every 1-*SD* increase in the latent factor, VIMSSQ-N, VIMSSQ-H, VIMSSQ-
322 D, VIMSSQ-F, and VIMSSQ-ES subscales are predicted to increase by .68, .88, .71, .73 and .77,
323 respectively. A moderate to high MacDonald's omega of .87 demonstrated good scale reliability
324 of the VIMSSQ.

325 **VIMSSQ and other variables**

326 Mean scores for participants' susceptibility to traditional motion sickness, migraines, and
327 dizziness are shown in Table 4. Independent samples *t* tests showed that females reported higher
328 scores than males with respect to the MSSQ-adult subscale, $t(288) = 5.051, p < .001, d = .57$, and
329 the MSSQ-child subscale, $t(279) = 2.32, p = .021, d = .27$. Non-parametric tests (Wilcoxon)
330 showed that females also reported significantly higher scores than males with regards to
331 migraines, $W = 14931.0, p < .001$, dizziness, $W = 13271.0, p = .032$, and syncope, $W = 14557.0,$
332 $p < .001$. Correlations were calculated for each of the VIMSSQ subscales, the MSSQ-child and
333 MSSQ-adult, migraine, dizziness, and age. Results are given in Table 5 and indicate that VIMS
334 and MS are significantly correlated with each other. Interestingly, we found significant, negative
335 correlations between age and all VIMSSQ subscales, indicating that VIMS is less severe with
336 increasing age.

VIMSSQ: DEVELOPMENT AND VALIDATION

337 **Table 4**

338 *Mean (SD) scores for MSSQ, migraine, and dizziness separated by sex*

Sex	Measure				
	MSSQ child (n = 293) ^a	MSSQ adult (n = 293) ^a	Migraine (n = 321)	SWID4 (n = 321)	Syncope (n = 321)
Female	8.34 (6.76)	6.83 (6.01)	1.68 (1.73)	0.26 (0.69)	0.28 (0.46)
Male	6.62 (5.85)	3.68 (4.67)	1.00 (1.41)	0.16 (0.67)	0.09 (0.28)
<i>p</i> value ^b	< .001	.021	< .001	.033	< .001

339 *Note.* ^aMSSQ data for 29 participants were incomplete and could not be calculated;

340 ^bSignificance level for sex comparisons (*t* test for MSSQ, Wilcoxon tests for migraine and
341 dizziness)

342

343 **Table 5**

344 *Correlations between VIMSSQ, MSSQ, migraine, dizziness, and age*

Measure	VIMSSQ subscale					
	Nausea	Headache	Dizziness	Fatigue	Eyestrain	Total score
MSSQ child ^a	.38**	.28**	.31**	.19**	.28**	.35**
MSSQ adult ^a	.47**	.39**	.29**	.27**	.37**	.44**
Migraine ^b	.16*	.36**	.14	.19**	.29**	.30**
SWID4 ^b	.16*	.14	.22**	.05	.14	.16*
Syncope ^b	.11	.26**	.24**	.18*	.22**	.25**
Age ^c	-.24**	-.36**	-.17**	-.26**	-.40**	-.37**

345 *Note.* ^a Pearson correlations (*n* = 293), ^b Spearman correlations (*n* = 322), ^c Age information for

346 three participants were missing; Pearson correlations (*n* = 319). **p* < .05, ***p* < .01

347 **Discussion: Survey study**

348 The results of the online survey delivered insights into the frequency and severity of
349 different VIMS-related symptoms associated with each device. We found that eyestrain is the
350 most common symptom reported by users, whereas nausea and dizziness are experienced less
351 frequently across all visual devices. Oculomotor issues such as eyestrain have been known to be
352 one of the primary symptoms of VIMS, and this family of symptoms is typically more prominent
353 than gastrointestinal disturbances in VIMS compared to traditional motion sickness (Keshavarz
354 et al., 2014; K. M. Stanney & Kennedy, 1997). Thus, it seems plausible that eyestrain was the
355 most common symptom when using visual devices.

356 We also found that females reported significantly higher VIMS scores compared to males
357 across all symptoms but nausea. Sex-related differences in VIMS (Flanagan et al., 2005;
358 Klosterhalfen et al., 2006) and traditional motion sickness (Dobie et al., 2001; K. M. Stanney et
359 al., 2003) have been documented in previous studies. The reason for these differences are not
360 well known; hormonal aspects have been discussed as a potential cause, as the menstruation
361 cycle has been shown to affect women's susceptibility to motion sickness (Golding et al., 2005;
362 Grunfeld & Gresty, 1998; Hemmerich et al., 2019). It has also been speculated that females may
363 be more open and more willing to report VIMS compared to men (Ladwig et al., 2000), but
364 scientific evidence supporting this claim is weak (Dobie et al., 2001). Note, however, that
365 Cohen's effect sizes indicate that the sex-related differences found for the VIMSSQ subscales
366 are rather weak or moderate at best. Furthermore, we found negative correlations between age
367 and the VIMSSQ subscales, suggesting that users report less VIMS with increasing age. This
368 finding is surprising, as laboratory research showed that older adults typically report more VIMS
369 compared to younger adults (Brooks et al., 2010; Keshavarz, Ramkhalawansingh, et al., 2018).

VIMSSQ: DEVELOPMENT AND VALIDATION

370 However, our findings could be due to the fact that older adults tend to use fewer visual displays
371 than younger adults and use them less frequently, which could explain the overall lower VIMS
372 scores. It could also be possible that older adults report less VIMS due to habituation as a result
373 of continuous exposure to visual devices. More thorough and systematic studies are needed to
374 better understand the relationship between VIMS and age.

375 Moderately strong correlations between the VIMSSQ scores and other related concepts
376 such as the susceptibility to traditional motion sickness, dizziness, and migraine were found.
377 These correlations suggest that the susceptibility to VIMS is indeed linked to the susceptibility to
378 traditional motion sickness, but that these two phenomena are also independent from each other
379 to some extent, highlighting the need to develop a tool that can specifically predict an
380 individual's susceptibility to VIMS.

381 With regards to the general usage of visual devices, we found that TV, 2D movies, and
382 smartphones are the most frequently used visual devices for dynamic visual content. In contrast,
383 VR glasses were not commonly used and more than 60% of all participants have never used VR
384 glasses before. This finding is somewhat surprising, given that VR devices are becoming more
385 popular in various domains, such as entertainment, research, or teaching, and have become more
386 affordable and accessible to a broader population. However, our findings suggest that VR is yet
387 to become mainstream and is still a novelty to the majority of survey participants. Around 30%
388 of participants indicated that VIMS-related symptoms make them reduce or fully avoid the use of
389 certain visual devices, particularly 3D movies. This demonstrates that VIMS is indeed a severe
390 issue that interrupts almost a third of users and requires them to adjust their behaviour.
391 Interestingly, the only sex-related difference with regards to the usage of devices showed for
392 videogames, with males playing significantly more videogames than females, supporting

VIMSSQ: DEVELOPMENT AND VALIDATION

393 previous studies that showed similar sex differences for video game usage (Ogletree & Drake,
394 2007; Terlecki et al., 2011). No other differences between males and females showed with
395 respect to the usage of visual displays.

396 The scale reliability of the VIMSSQ was high as indicated by MacDonald's Omega and
397 was similar to previous findings (Golding & Keshavarz, 2017). A one-factorial solution for the
398 VIMSSQ was found to be the best fit, suggesting that all subscales of the VIMSSQ indeed
399 measure the latent construct of VIMS susceptibility. Of note, headache and eyestrain had a
400 stronger influence on overall VIMS susceptibility compared to dizziness, fatigue, and nausea. As
401 a next step, we empirically tested the efficacy of the VIMSSQ questionnaire to predict VIMS
402 provoked in an experimental study. The next section will describe the validation process for the
403 VIMSSQ.

404 **Part 2: Validating the VIMSSQ – Experimental study**

405 **Methods**

406 **Participants**

407 Twenty-three healthy younger adults (15 females, $M_{age} = 25.26$ years, $SD = 3.89$)
408 participated in an experimental study at The KITE Research Institute, the research arm of the
409 Toronto Rehabilitation Institute at the University Health Network (UHN). The study complied
410 with the tenets of the Declaration of Helsinki and was approved by the Institutional Review
411 Board at UHN. Participants were naïve with respect to the purpose of the study. Written consent
412 was obtained prior to the beginning of the study and participants were reimbursed for their time
413 commitment.

414 **Study design, stimuli, and experimental procedure**

Commented [KB1]: Brandy: I added more details about the study, please check carefully and edit if needed

VIMSSQ: DEVELOPMENT AND VALIDATION


415 The objective of this study was to investigate the influence of multisensory cues on the
416 perception of illusory self-motion, orvection. Asvection and VIMS are known to often co-occur
417 (see Keshavarz et al., 2015, for an overview), we saw this study as an appropriate choice to
418 validate the VIMSSQ. Participants were seated in a rotatable chair in the center of a dome-
419 shaped laboratory (KITE's StreetLab) with five projectors creating a large, curved image with a
420 field-of-view of 240° horizontally and 110° vertically surrounding them. Participants were
421 exposed to a revolving stimulus that induced the sensation of self-motion along the yaw axis
422 (circularvection). The stimulus contained visual, auditory, and/or tactile cues (see Figure 6): the
423 visual cues consisted of a photorealistic virtual office scene, the auditory cues contained three
424 stationary sound sources (continuous sound of a fan, telephone, and printer) placed within the
425 same virtual office scene, and the tactile cues were provided via a circular handrail within reach
426 that rotated around the participants. All participants were exposed to trials that either included a
427 single sensory input (visual-only, auditory-only, tactile-only), a combination of two (audio-
428 visual, audio-tactile, visual-tactile), and a combination of all three sensory cues (audio-visual-
429 tactile). Additionally, the visible field-of-view (FOV) was systematically manipulated by
430 occluding the periphery of the projection screen to 0° (no visual cues), 45°(small FOV), 120°
431 (medium FOV), and 240° (large FOV). Thus, a 2 x 2 x 4 factorial design including the within-
432 subjects factors visual cues (no visual cues, small FOV, medium FOV, large FOV), auditory cues
433 (present, absent), and tactile cues (present, absent) was chosen, resulting in 16 trials with
434 different sensory cue combinations. Each trial was 45s long (2.5s acceleration phase, 40s
435 constant circular motion, 2.5s deceleration) and was repeated four times, resulting in a total of 64
436 trials with a combined duration of approximately 45 minutes. Participants were asked to focus on
437 a fixation point superimposed at the center of the screen. Between trials, the screen was

VIMSSQ: DEVELOPMENT AND VALIDATION

438 blackened and participants were asked to verbally rate vection intensity and duration. Trials were
439 separated into 4 different blocks (16 trials each, randomized order) with a short rest break
440 between the blocks. The vection results and their relationship to multisensory cues are presented
441 and discussed elsewhere (Murovec et al., 2020).

442 **Figure 6**

443 *Picture of the experimental setup showing the visual, auditory, and tactile stimuli.*



444 Prior to the experiment,
445 participants filled out the same questionnaires used for the online survey, including the
446 VIMSSQ, the avoidance question, the MSSQ-short, the Migraine Screen Questionnaire, the
447 SWID4, and the single binary item concerning the susceptibility to vasovagal syncope. Note that
448 the response format for the avoidance question was modified to match the VIMSSQ response
449 format (0 = *never*, 1 = *rarely*, 1 = *sometimes*, 3 = *often*). Following the experiment (i.e., after the
450 last trial), VIMS symptomology was measured using the Simulator Sickness Questionnaire
451 (SSQ; Kennedy et al., 1993). The SSQ contains 16 items associated with VIMS, such as nausea,
452 dizziness, fatigue, or blurred vision, that have to be rated on a scale from 0 (*not at all*) to 3

VIMSSQ: DEVELOPMENT AND VALIDATION

453 (*severe*). Three subscales (nausea, disorientation, oculomotor) as well as a total score can be
454 generated using specific factor weightings suggested by Kennedy et al. (1993).

455 **Results**

456 All participants reported elevated levels of VIMS after the experiment as measured by the
457 SSQ subscales nausea ($M = 22.81$, $SD = 19.02$), oculomotor ($M = 28.34$, $SD = 19.01$),
458 disorientation ($M = 36.92$, $SD = 39.95$), and the total score ($M = 32.85$, $SD = 24.37$). The results
459 for the VIMSSQ subscales and the total score, the MSSQ-short, the Migraine Screen
460 Questionnaire, and the SWID4 are given in Table 6. With regards to avoidance, 39.1% of the
461 participants reported that they occasionally avoid visual devices due to VIMS (17.4% rarely,
462 21.7% sometimes), whereas the majority of the participants do not avoid using visual devices
463 (60.9%). Four of the 23 participants (17.4%) experienced syncope in the past.

464 **Table 6**

465 *Mean and SD for all questionnaire data*

Measure	Female (<i>n</i> = 15)		Male (<i>n</i> = 8)	
	<i>M</i>	<i>SD</i>	<i>M</i>	<i>SD</i>
VIMSSQ Nausea	4.98	6.25	1.30	1.60
VIMSSQ Headache	6.25	5.34	2.09	1.90
VIMSSQ Dizziness	3.95	4.09	0.78	0.93
VIMSSQ Fatigue	5.68	5.95	1.99	3.70
VIMSSQ Eyestrain	8.37	6.20	5.21	4.35
VIMSSQ total score	29.23	19.05	11.36	7.76
Migraine	1.60	2.00	1.13	2.00
SWID	0.27	1.00	0.00	0.00
MSSQ-child	9.69	7.61	4.66	3.30
MSSQ-adult	7.98	5.33	2.50	2.13

466 Linear regression models were calculated to estimate the amount of VIMS variance
 467 (measured by the SSQ total score) explained by different predictive variables. That is, the
 468 VIMSSQ total score, the MSSQ-short subscales child and adult, the Migraine Screen
 469 Questionnaire total score, the SWID4 total score, the avoidance tendency score, and the syncope
 470 score were included in the regression model. A stepwise forward approach was chosen.
 471 Correlations between the SSQ and the predictive factors are shown in Table 7.

VIMSSQ: DEVELOPMENT AND VALIDATION

472 **Table 7**

473 *Correlations (Pearson) between the SSQ total score and the predictor variables*

	Predictor variable						
	VIMSSQ total score	avoidance	MSSQ child	MSSQ adult	Migraine	SWID	Syncope
SSQ	.60**	.69**	.38*	.49**	.46*	.11	.36*

474 Note: * $p < .05$, ** $p < .01$

475 Prior to the stepwise procedure, an initial baseline regression model was constructed to
 476 examine the raw relationship between the VIMSSQ total score and the SSQ total score (Figure
 477 5). This model was found to be significant, $F(1, 21) = 11.52, p = .003$, accounting for 35.4%
 478 (multiple R^2) of the variance in VIMS symptomology. Specifically, it was found that the SSQ
 479 total score is predicted to increase by .595 *SD* units for every 1 *SD* increase in the VIMSSQ total
 480 score. The model that explained the largest amount of variance contained the VIMSSQ total
 481 score, avoidance, and syncope as predictors, accounting for 59% (adjusted R^2) of the total
 482 variance in the SSQ total score. This model was shown to be a significant improvement from the
 483 baseline model, $F(2, 19) = 7.85, p = .003$. The standardized regression coefficients indicated that
 484 avoidance had the strongest influence on the SSQ total score, followed by the VIMSSQ total
 485 score and syncope, where every 1 *SD* increase in these variables predicted an increase in the SSQ
 486 total score of .506, .381, and .196, respectively. No other variables significantly increased the
 487 explained variance further.


Commented [KB2]: Brandy: please check John's comment about this sentence:

The other thing about this statement is if you look at fig 5, then a 1SD increase in VIMSSQ would surely produce a bigger increase in SSQ? 1 SD of VIMSSQ is F 19.05 or M 7.76 (Table 6). If you move say 10 or more VIMSSQ units on x axis, you can eyeball it and see the increase in SSQ must be more like a 10 or more point increase in SSQ on y axis. Maybe I have misunderstood something here and we are talking SDs of SSQ or z-scores? Or ratios?? Might be worth checking elsewhere where moves in SD units are used in the text?

I assume that you wanted to say that a SD of avoidance score increased the SSQ score by .506 SD of the SSQ? Please edits this section accordingly.

488 **Figure 5**

489 *Scatterplot displaying the relationship between the SSQ total score and the VIMSSQ total score*
490 *(multiple $R^2 = 0.354$)*



491

492 **Discussion: Experimental study**

493 The results of the experimental study demonstrated that the VIMSSQ is a valuable tool to
494 predict the occurrence of VIMS, particularly when combined with other questionnaires; the
495 VIMSSQ alone explained 34% of VIMS variance as measured by the SSQ total score, and this
496 score increased to 59% when questions about avoidance tendencies and syncope experiences
497 were added. In contrast, adding the MSSQ (child and adult) or questions about migraines and
498 dizziness did not increase the amount of explained variance.

499 These results are in support of previous findings, suggesting that the VIMSSQ can be
500 useful in predicting the occurrence of VIMS (Golding & Keshavarz, 2017; Keshavarz et al.,
501 2019). For instance, a study by Keshavarz et al. (2019) measured the level of VIMS in older and
502 younger adults who participated in a simulated driving study. The VIMSSQ was administered
503 before the drive and was compared to the level of reported VIMS as measured via the Fast

VIMSSQ: DEVELOPMENT AND VALIDATION

504 Motion Sickness Scale (FMS, Keshavarz & Hecht, 2011). Results showed that the VIMSSQ
505 worked equally well for younger and older adults and that the VIMSSQ subscale nausea alone
506 was able to predict approximately a third of the variance in the FMS data. When other variables
507 were added, the predictive power increased to more than 40% of the variance.

508 **General Discussion and Conclusion**

509 The aim of the present paper was to introduce the VIMSSQ as a questionnaire that can
510 estimate an individual's susceptibility to VIMS. Thus, the present paper described the
511 development process of the VIMSSQ, gathered data from a large sample in order to establish
512 first normative data that could be used as a benchmark, and demonstrated in an experimental
513 study that the VIMSSQ can be a useful tool predicting the occurrence of VIMS as measured by
514 the SSQ. Together with our previous work on the VIMSSQ (Golding & Keshavarz, 2017;
515 Keshavarz et al., 2019), we are gaining confidence in recommending the use of the VIMSSQ in
516 combination with other scales and questions to detect those users of visual devices who might be
517 at elevated risk of experiencing VIMS. Notably, the VIMSSQ seems superior to other existing
518 questionnaires (e.g., MSSQ) in predicting the occurrence of VIMS.

519 Despite the promising results, additional investigations, particularly with larger
520 participant samples across various populations and various experimental settings (e.g., different
521 visual displays, different stimuli), are highly desirable to further determine the predictive power
522 of the VIMSSQ. For instance, the scatterplot shown in Figure 5 depicts an "outlier" with a very
523 high VIMSSQ score (above 90th percentile of the norm). Removing this participant from the
524 regression model substantially increased the explained variance of the SSQ to 75%. Thus, studies
525 with larger sample sizes are recommended to establish a more robust model of the VIMSSQ's
526 predictive power. In addition, future studies should also compare the VIMSSQ to different VIMS

VIMSSQ: DEVELOPMENT AND VALIDATION

527 measures that are more tailored to certain visual devices. Although the SSQ is the most
528 commonly used questionnaire for assessing VIMS, it was originally designed for the use of
529 driving and flight simulators. More recent studies questioned the appropriateness of the SSQ for
530 instance in the context of VR, suggesting that modified versions of the SSQ might be more
531 useful (Sevinc & Berkman, 2020). Thus, we recommend to further investigate the predictive
532 power of the VIMSSQ for alternative measures of VIMS.

533 One of the main disadvantages of the VIMSSQ is that it is quite lengthy and can be
534 somewhat overwhelming for participants. Thus, a short version of the VIMSSQ was recently
535 proposed and tested (Golding et al., submitted). The short version of the VIMSSQ has a similar
536 structure to the VIMSSQ (i.e., same five symptoms), but does not differentiate between the
537 different visual devices. Instead, users are asked to rate the occurrence of nausea, headache,
538 dizziness, fatigue, and eyestrain for all visual displays together (ranging from 0 = *never* to 3 =
539 *often*), resulting in a total of 5 symptom items. The avoidance question from the VIMSSQ was
540 retained, making the short version of the VIMSSQ a 6-item long questionnaire. In the
541 experimental study by Golding et al. (submitted), 30 participants were exposed to a nauseating
542 visual stimulus and filled out the short version of the VIMSSQ together with the same set of
543 questionnaires described in the present study (e.g., migraine, SWID4, syncope, MSSQ). Similar
544 to the present findings, the VIMSSQ-short explained approximately 34% of the total variance of
545 VIMS as measured by the VIMSSQ, and this number increased to 56% when other
546 questionnaires were added. This is first proof that a short version of the VIMSSQ might be
547 similarly effective to the long version of the VIMSSQ. However, a direct comparison between
548 the VIMSSQ long and short version is needed in the future and should be conducted with a
549 larger sample size.

VIMSSQ: DEVELOPMENT AND VALIDATION

- 550 **Key points**
- 551 - Visually induced motion sickness (VIMS) is a common issue when using visual devices
 - 552 - Most common symptoms include eyestrain, fatigue, headache, dizziness, and nausea
 - 553 - Two studies were conducted to develop and validate the Visually Induced Motion
 - 554 Sickness Susceptibility Questionnaire (VIMSSQ)
 - 555 - The VIMSSQ can be a valuable tool to estimate individual susceptibility to VIMS

556

References

- 557 Adamovich, S. V., Fluett, G. G., Tunik, E., & Merians, A. S. (2009). Sensorimotor Training in
558 Virtual Reality: A Review. *NeuroRehabilitation*, 25(1), 29. [https://doi.org/10.3233/NRE-](https://doi.org/10.3233/NRE-2009-0497)
559 2009-0497
- 560 Bates, J. (1992). Virtual Reality, Art, and Entertainment. *Presence: Teleoperators and Virtual*
561 *Environments*, 1(1), 133–138. <https://doi.org/10.1162/pres.1992.1.1.133>
- 562 Bos, J. E. (2015). Less sickness with more motion and/or mental distraction. *Journal of*
563 *Vestibular Research: Equilibrium & Orientation*, 25(1), 23–33.
564 <https://doi.org/10.3233/VES-150541>
- 565 Bos, J. E., Bles, W., & Groen, E. L. (2008). A theory on visually induced motion sickness.
566 *Displays*, 29(2), 47–57. <https://doi.org/10.1016/j.displa.2007.09.002>
- 567 Bos, J. E., de Vries, S. C., van Emmerik, M. L., & Groen, E. L. (2010). The effect of internal and
568 external fields of view on visually induced motion sickness. *Applied Ergonomics*, 41(4),
569 516–521. <https://doi.org/10.1016/j.apergo.2009.11.007>
- 570 Bosser, G., Caillet, G., Gauchard, G., Marçon, F., & Perrin, P. (2006). Relation between motion
571 sickness susceptibility and vasovagal syncope susceptibility. *Brain Research Bulletin*,
572 68(4), 217–226. <https://doi.org/10.1016/j.brainresbull.2005.05.031>
- 573 Bronstein, A. M., Golding, J. F., Gresty, M. A., Mandalà, M., Nuti, D., Shetye, A., & Silove, Y.
574 (2010). The social impact of dizziness in London and Siena. *Journal of Neurology*,
575 257(2), 183–190. <https://doi.org/10.1007/s00415-009-5287-z>
- 576 Brooks, J. O., Goodenough, R. R., Crisler, M. C., Klein, N. D., Alley, R. L., Koon, B. L., Logan,
577 W. C., Ogle, J. H., Tyrrell, R. A., & Wills, R. F. (2010). Simulator sickness during

VIMSSQ: DEVELOPMENT AND VALIDATION

- 578 driving simulation studies. *Accident Analysis & Prevention*, 42(3), 788–796.
579 <https://doi.org/10.1016/j.aap.2009.04.013>
- 580 Bubka, A., Bonato, F., & Palmisano, S. (2007). Expanding and contracting optical flow patterns
581 and simulator sickness. *Aviation, Space, and Environmental Medicine*, 78(4), 383–386.
- 582 Cobb, S. V. (1999). Measurement of postural stability before and after immersion in a virtual
583 environment. *Applied Ergonomics*, 30(1), 47–57.
- 584 Cobb, S. V. G., Nichols, S., Ramsey, A., & Wilson, J. R. (1999). Virtual Reality-Induced
585 Symptoms and Effects (VRISE). *Presence: Teleoperators and Virtual Environments*,
586 8(2), 169–186. <https://doi.org/10.1162/105474699566152>
- 587 Curry, C., Li, R., Peterson, N., & Stoffregen, T. A. (2020). Cybersickness in Virtual Reality
588 Head-Mounted Displays: Examining the Influence of Sex Differences and Vehicle
589 Control. *International Journal of Human–Computer Interaction*, 36(12), 1161–1167.
590 <https://doi.org/10.1080/10447318.2020.1726108>
- 591 D’Amour, S., Bos, J. E., & Keshavarz, B. (2017). The efficacy of airflow and seat vibration on
592 reducing visually induced motion sickness. *Experimental Brain Research*, 235(9), 2811–
593 2820. <https://doi.org/10.1007/s00221-017-5009-1>
- 594 Dobie, T., McBride, D., Dobie, T., Jr, & May, J. (2001). The effects of age and sex on
595 susceptibility to motion sickness. *Aviation, Space, and Environmental Medicine*, 72(1),
596 13–20.
- 597 Domeyer, J. E., Cassavaugh, N. D., & Backs, R. W. (2013). The use of adaptation to reduce
598 simulator sickness in driving assessment and research. *Accident Analysis & Prevention*,
599 53, 127–132. <https://doi.org/10.1016/j.aap.2012.12.039>

VIMSSQ: DEVELOPMENT AND VALIDATION

- 600 Duh, H. B.-L., Lin, J. J., Kenyon, R. V., Parker, D. E., & Furness, T. A. (2002). Effects of
601 characteristics of image quality in an immersive environment. *Presence: Teleoperators
602 and Virtual Environments, 11*(3), 324–332.
- 603 Duh, H. B.-L., Parker, D. E., & Furness, T. A. (2004). An independent visual background
604 reduced simulator sickness in a driving simulator. *Presence: Teleoperators and Virtual
605 Environments, 13*(5), 578–588.
- 606 Flanagan, M. B., May, J. G., & Dobie, T. G. (2005). Sex differences in tolerance to visually-
607 induced motion sickness. *Aviation, Space, and Environmental Medicine, 76*(7), 642–646.
- 608 Flora, D. B., & Curran, P. J. (2004). An Empirical Evaluation of Alternative Methods of
609 Estimation for Confirmatory Factor Analysis With Ordinal Data. *Psychological Methods,
610 9*(4), 466–491. <https://doi.org/10.1037/1082-989X.9.4.466>
- 611 Frank, L. H., Casali, J. G., & Wierwille, W. W. (1988). Effects of visual display and motion
612 system delays on operator performance and uneasiness in a driving simulator. *Human
613 Factors, 30*(2), 201–217.
- 614 Frey, A., Hartig, J., Ketzler, A., Zinkernagel, A., & Moosbrugger, H. (2007). The use of virtual
615 environments based on a modification of the computer game Quake III Arena® in
616 psychological experimenting. *Computers in Human Behavior, 23*(4), 2026–2039.
617 <https://doi.org/10.1016/j.chb.2006.02.010>
- 618 Golding, J. F. (1998). Motion sickness susceptibility questionnaire revised and its relationship to
619 other forms of sickness. *Brain Research Bulletin, 47*(5), 507–516.
- 620 Golding, J. F. (2006). Predicting individual differences in motion sickness susceptibility by
621 questionnaire. *Personality and Individual Differences, 41*(2), 237–248.
622 <https://doi.org/10.1016/j.paid.2006.01.012>

VIMSSQ: DEVELOPMENT AND VALIDATION

- 623 Golding, J. F., & Gresty, M. A. (2005). Motion sickness. *Current Opinion in Neurology*, 18(1),
624 29–34.
- 625 Golding, J. F., & Gresty, M. A. (2015). Pathophysiology and treatment of motion sickness:
626 *Current Opinion in Neurology*, 28(1), 83–88.
627 <https://doi.org/10.1097/WCO.000000000000163>
- 628 Golding, J. F., Kadzere, P., & Gresty, M. A. (2005). Motion sickness susceptibility fluctuates
629 through the menstrual cycle. *Aviation, Space, and Environmental Medicine*, 76(10), 970–
630 973.
- 631 Golding, J. F., & Keshavarz, B. (2017). *Predictors of Visually Induced Motion Sickness*
632 *Susceptibility* [Oral presentation]. 6th International Conference on Visually Induced
633 Motion Sensations VIMS 2017, Toronto, Canada.
- 634 Golding, J. F., & Patel, M. (2017). Meniere's, migraine, and motion sickness. *Acta Oto-*
635 *Laryngologica*, 137(5), 495–502. <https://doi.org/10.1080/00016489.2016.1255775>
- 636 Grunfeld, E., & Gresty, M. A. (1998). Relationship between motion sickness, migraine and
637 menstruation in crew members of a “round the world” yacht race. *Brain Research*
638 *Bulletin*, 47(5), 433–436.
- 639 Hemmerich, W. A., Shahal, A., & Hecht, H. (2019). Predictors of visually induced motion
640 sickness in women. *Displays*, 58, 27–32. <https://doi.org/10.1016/j.displa.2018.11.005>
- 641 Hill, K. J., & Howarth, P. A. (2000). Habituation to the side effects of immersion in a virtual
642 environment. *Displays*, 21(1), 25–30. [https://doi.org/10.1016/S0141-9382\(00\)00029-9](https://doi.org/10.1016/S0141-9382(00)00029-9)
- 643 Kennedy, R. S., Lilienthal, M. G., Berbaum, K. S., Baltzley, D. R., & McCauley, M. E. (1989).
644 Simulator sickness in U.S. Navy flight simulators. *Aviation, Space, and Environmental*
645 *Medicine*, 60(1), 10–16.

VIMSSQ: DEVELOPMENT AND VALIDATION

- 646 Kennedy, Robert S., Drexler, J., & Kennedy, R. C. (2010). Research in visually induced motion
647 sickness. *Applied Ergonomics*, 41(4), 494–503.
648 <https://doi.org/10.1016/j.apergo.2009.11.006>
- 649 Kennedy, Robert S., Lane, N. E., Berbaum, K. S., & Lilienthal, M. G. (1993). Simulator
650 Sickness Questionnaire: An Enhanced Method for Quantifying Simulator Sickness. *The*
651 *International Journal of Aviation Psychology*, 3(3), 203–220.
652 https://doi.org/10.1207/s15327108ijap0303_3
- 653 Keshavarz, B. (2016). Exploring Behavioral Methods to Reduce Visually Induced Motion
654 Sickness in Virtual Environments. In S. Lackey & R. Shumaker (Eds.), *Virtual,*
655 *Augmented and Mixed Reality* (Vol. 9740, pp. 147–155). Springer International
656 Publishing. http://link.springer.com/10.1007/978-3-319-39907-2_14
- 657 Keshavarz, B., & Hecht, H. (2011). Validating an Efficient Method to Quantify Motion Sickness.
658 *Human Factors: The Journal of the Human Factors and Ergonomics Society*, 53(4), 415–
659 426. <https://doi.org/10.1177/0018720811403736>
- 660 Keshavarz, B., & Hecht, H. (2014). Pleasant music as a countermeasure against visually induced
661 motion sickness. *Applied Ergonomics*, 45(3), 521–527.
662 <https://doi.org/10.1016/j.apergo.2013.07.009>
- 663 Keshavarz, B., Hecht, H., & Lawson, B. D. (2014). Visually induced motion sickness:
664 Characteristics, causes, and countermeasures. In K. S. Hale & K. M. Stanney (Eds.),
665 *Handbook of Virtual Environments: Design, Implementation, and Applications* (2nd ed.,
666 pp. 648–697). CRC Press.

VIMSSQ: DEVELOPMENT AND VALIDATION

- 667 Keshavarz, B., Philipp-Muller, A. E., Hemmerich, W., Riecke, B. E., & Campos, J. L. (2018).
668 The effect of visual motion stimulus characteristics on vection and visually induced
669 motion sickness. *Displays*. <https://doi.org/10.1016/j.displa.2018.07.005>
- 670 Keshavarz, B., Ramkhalawansingh, R., Haycock, B., Shahab, S., & Campos, J. L. (2018).
671 Comparing simulator sickness in younger and older adults during simulated driving under
672 different multisensory conditions. *Transportation Research Part F: Traffic Psychology
673 and Behaviour*, 54, 47–62. <https://doi.org/10.1016/j.trf.2018.01.007>
- 674 Keshavarz, B., Riecke, B. E., Hettinger, L. J., & Campos, J. L. (2015). Vection and visually
675 induced motion sickness: How are they related? *Frontiers in Psychology*, 6.
676 <https://doi.org/10.3389/fpsyg.2015.00472>
- 677 Keshavarz, B., Saryazdi, R., Campos, J. L., & Golding, J. F. (2019). Introducing the VIMSSQ:
678 Measuring susceptibility to visually induced motion sickness. *Proceedings of the Human
679 Factors and Ergonomics Society Annual Meeting*, 63(1), 2267–2271.
680 <https://doi.org/10.1177/1071181319631216>
- 681 Klosterhalfen, S., Pan, F., Kellermann, S., & Enck, P. (2006). Gender and race as determinants
682 of nausea induced by circular vection. *Gender Medicine*, 3(3), 236–242.
- 683 Klüver, M., Herrigel, C., Preuss, S., & Hecht, H. (2015). Comparing the Incidence of Simulator
684 Sickness in Five Different Driving Simulators. *Proceedings of the Driving Simulation
685 Conference Europe 2015*, 87–94.
- 686 Ladwig, K. H., Marten-Mittag, B., Formanek, B., & Dammann, G. (2000). Gender differences of
687 symptom reporting and medical health care utilization in the German population.
688 *European Journal of Epidemiology*, 16(6), 511–518.
689 <https://doi.org/10.1023/a:1007629920752>

VIMSSQ: DEVELOPMENT AND VALIDATION

- 690 Láinez, M. J., Castillo, J., Domínguez, M., Palacios, G., Díaz, S., & Rejas, J. (2010). New uses
691 of the Migraine Screen Questionnaire (MS-Q): Validation in the Primary Care setting and
692 ability to detect hidden migraine. MS-Q in Primary Care. *BMC Neurology*, *10*(1), 39.
693 <https://doi.org/10.1186/1471-2377-10-39>
- 694 Lawson, B. D. (2014). Motion sickness symptomatology and origins. In K. S. Hale & K. M.
695 Stanney (Eds.), *Handbook of Virtual Environments: Design, Implementation, and*
696 *Applications* (2nd ed., pp. 531–599). CRC Press.
- 697 Loomis, J. M., Blascovich, J. J., & Beall, A. C. (1999). Immersive virtual environment
698 technology as a basic research tool in psychology. *Behavior Research Methods,*
699 *Instruments, & Computers*, *31*(4), 557–564. <https://doi.org/10.3758/BF03200735>
- 700 Massetti, T., da Silva, T. D., Crocetta, T. B., Guarnieri, R., de Freitas, B. L., Bianchi Lopes, P.,
701 Watson, S., Tonks, J., & de Mello Monteiro, C. B. (2018). The Clinical Utility of Virtual
702 Reality in Neurorehabilitation: A Systematic Review. *Journal of Central Nervous System*
703 *Disease*, *10*. <https://doi.org/10.1177/1179573518813541>
- 704 Moss, J. D., & Muth, E. R. (2011). Characteristics of Head-Mounted Displays and Their Effects
705 on Simulator Sickness. *Human Factors: The Journal of the Human Factors and*
706 *Ergonomics Society*, *53*(3), 308–319. <https://doi.org/10.1177/0018720811405196>
- 707 Murovec, B., Spaniol, J., Campos, J. L., & Keshavarz, B. (2020, October 6). *The role of visual,*
708 *auditory, and tactile cues in the perception of illusory self-motion (vection)*. 3rd
709 Interdisciplinary Navigation Symposium, Virtual Conference.
- 710 Muth, E. R., Stern, R. M., Thayer, J. F., & Koch, K. L. (1996). Assessment of the multiple
711 dimensions of nausea: The Nausea Profile (NP). *Journal of Psychosomatic Research*,
712 *40*(5), 511–520.

VIMSSQ: DEVELOPMENT AND VALIDATION

- 713 Ogletree, S. M., & Drake, R. (2007). College Students' Video Game Participation and
714 Perceptions: Gender Differences and Implications. *Sex Roles, 56*(7), 537–542.
715 <https://doi.org/10.1007/s11199-007-9193-5>
- 716 Palmisano, S., Bonato, F., Bubka, A., & Folder, J. (2007). Vertical Display Oscillation Effects on
717 Forward Vection and Simulator Sickness. *Aviation, Space, and Environmental Medicine,*
718 *78*(10), 951–956. <https://doi.org/10.3357/ASEM.2079.2007>
- 719 Peck, K., Russo, F., Campos, J. L., & Keshavarz, B. (2020). Examining potential effects of
720 arousal, valence, and likability of music on visually induced motion sickness.
721 *Experimental Brain Research.* <https://doi.org/10.1007/s00221-020-05871-2>
- 722 Prothero, J. D., Draper, M. H., Furness, T. A., 3rd, Parker, D. E., & Wells, M. J. (1999). The use
723 of an independent visual background to reduce simulator side-effects. *Aviation, Space,*
724 *and Environmental Medicine, 70*(3 Pt 1), 277–283.
- 725 Radianti, J., Majchrzak, T. A., Fromm, J., & Wohlgenannt, I. (2020). A systematic review of
726 immersive virtual reality applications for higher education: Design elements, lessons
727 learned, and research agenda. *Computers & Education, 147,* 103778.
728 <https://doi.org/10.1016/j.compedu.2019.103778>
- 729 Rine, R. M., Schubert, M. C., & Balkany, T. J. (1999). Visual-vestibular habituation and balance
730 training for motion sickness. *Physical Therapy, 79*(10), 949–957.
- 731 Rizzo, A. A., Wiederhold, M., & Buckwalter, J. G. (1998). Basic issues in the use of virtual
732 environments for mental health applications. *Studies in Health Technology and*
733 *Informatics, 58,* 21–42.

VIMSSQ: DEVELOPMENT AND VALIDATION

- 734 Rizzo, M. "Skip." (2014). Clinical virtual reality. In K. S. Hale & K. M. Stanney (Eds.),
735 *Handbook of Virtual Environments: Design, Implementation, and Applications* (2nd ed.,
736 pp. 1159–1204). CRC Press, Taylor & Francis Group.
- 737 Rosseel, Y. (2012). lavaan: An R Package for Structural Equation Modeling. *Journal of*
738 *Statistical Software*, 48(1), 1–36. <https://doi.org/10.18637/jss.v048.i02>
- 739 Sevinc, V., & Berkman, M. I. (2020). Psychometric evaluation of Simulator Sickness
740 Questionnaire and its variants as a measure of cybersickness in consumer virtual
741 environments. *Applied Ergonomics*, 82, 102958.
742 <https://doi.org/10.1016/j.apergo.2019.102958>
- 743 Smither, J. A.-A., Mouloua, M., & Kennedy, R. (2008). Reducing Symptoms of Visually
744 Induced Motion Sickness Through Perceptual Training. *The International Journal of*
745 *Aviation Psychology*, 18(4), 326–339. <https://doi.org/10.1080/10508410802346921>
- 746 Stanney, K., Fidopiastis, C., & Foster, L. (2020). Virtual Reality Is Sexist: But It Does Not Have
747 to Be. *Frontiers in Robotics and AI*, 7. <https://doi.org/10.3389/frobt.2020.00004>
- 748 Stanney, K. M., Hale, K. S., Nahmens, I., & Kennedy, R. S. (2003). What to Expect from
749 Immersive Virtual Environment Exposure: Influences of Gender, Body Mass Index, and
750 Past Experience. *Human Factors: The Journal of the Human Factors and Ergonomics*
751 *Society*, 45(3), 504–520. <https://doi.org/10.1518/hfes.45.3.504.27254>
- 752 Stanney, K. M., & Kennedy, R. S. (1997). The Psychometrics of Cybersickness. *Commun. ACM*,
753 40(8), 66–68. <https://doi.org/10.1145/257874.257889>
- 754 Stanney, K. M., Kennedy, R. S., Drexler, J. M., & Harm, D. L. (1999). Motion sickness and
755 proprioceptive aftereffects following virtual environment exposure. *Applied Ergonomics*,
756 30(1), 27–38.

VIMSSQ: DEVELOPMENT AND VALIDATION

- 757 Stanney, K. M., Mourant, R. R., & Kennedy, R. S. (1998). Human Factors Issues in Virtual
758 Environments: A Review of the Literature. *Presence*, 7(4), 327–351.
759 <https://doi.org/10.1162/105474698565767>
- 760 Stanney, K. M., Salvendy, G., Deisinger, J., DiZio, P., Ellis, S., Ellison, J., Fogleman, G.,
761 Gallimore, J., Singer, M., Hettinger, L., Kennedy, R., Lackner, J., Lawson, B., Maida, J.,
762 Mead, A., Mon-Williams, M., Newman, D., Piantanida, T., Reeves, L., ... Witmer, B.
763 (1998). Aftereffects and sense of presence in virtual environments: Formulation of a
764 research and development agenda. *International Journal of Human-Computer*
765 *Interaction*, 10(2), 135–187. https://doi.org/10.1207/s15327590ijhc1002_3
- 766 Terlecki, M., Brown, J., Harner-Steciw, L., Irvin-Hannum, J., Marchetto-Ryan, N., Ruhl, L., &
767 Wiggins, J. (2011). Sex Differences and Similarities in Video Game Experience,
768 Preferences, and Self-Efficacy: Implications for the Gaming Industry. *Current*
769 *Psychology*, 30(1), 22–33. <https://doi.org/10.1007/s12144-010-9095-5>
- 770 Yen Pik Sang, F. D., Billar, J. P., Golding, J. F., & Gresty, M. A. (2003). Behavioral methods of
771 alleviating motion sickness: Effectiveness of controlled breathing and a music audiotape.
772 *Journal of Travel Medicine*, 10(2), 108–111.
- 773 Yen Pik Sang, F. D., Golding, J. F., & Gresty, M. A. (2003). Suppression of sickness by
774 controlled breathing during mildly nauseogenic motion. *Aviation, Space, and*
775 *Environmental Medicine*, 74(9), 998–1002.
- 776

777

Biographies

778 *Behrang Keshavarz* is a Scientist at The KITE Research Institute-University Health Network and
779 an Assistant Professor (adjunct) at the Department of Psychology at Ryerson University,
780 Toronto, Canada. He received his PhD in General and Experimental Psychology from the
781 Johannes Gutenberg University Mainz, Germany, in 2012.

782

783 *Brandy Murovec* is a PhD student at The KITE Research Institute-University Health Network
784 and the Department of Psychology at Ryerson University, Toronto, Canada. She received her
785 Masters of Arts in Psychology from Ryerson University, Canada, in 2020.

786

787 *Niroshica Mohanathas* is a PhD student at The KITE Research Institute-University Health
788 Network and the Department of Psychology at the University of Toronto, Toronto, Canada. She
789 received her Masters of Arts in Psychology from the University of Toronto, Canada, in 2020.

790

791 *John F. Golding* is a Professor at the Department of Psychology at the University of Westminster
792 in London, UK. He received his PhD in Experimental Psychology from Oxford University, UK,
793 in 1980.